Neurosurgery

Integra LifeSciences Holdings Corporation has announced the launch of the Integra® CUSA® NXT Inferior Forward Bone Tip for its CUSA® NXT Ultrasonic Tissue Ablation System.

With effect from 1st June 2012, Tissuemed Ltd. and Medtronic Inc. have agreed that the medtech giant’s distribution of Tissuemed’s dural sealant film will revert back to Tissuemed. In a statement on its website Tissuemed states this is a commercial decision to enable it to actively control commercialisation of its core sealant product.

Hydrogel sealants have a habit of clogging in their applicator nozzles, a problem Hyperbranch reckon they’ve solved with their newly CE marked Adherus™ Autospray device.

Stereotactic Radiosurgery techniques are at the forefront of events at this week’s AANS meeting. Varian Medical Systems Inc is demonstrating its wares in what is becoming the gold standard treatment option in specific brain and spinal tumors.

Challenges for Integra as sales grows at slower rate than costs.

Clinical results from a study on the use of flow diversion in peripheral neurological vessels suggest the therapeutic solution has a place.

In short Stryker’s brain stent has been used in USA since 2005 on a Humanitarian Device Exemption (HDE) basis and … continue reading “Stryker’s Wingspan: A Regulatory Conundrum For FDA?”

Covidien’s stent-like clot retrieval device, SOLITAIRE FR, worked well enough in this randomised study to persuade the safety monitoring committee to end the trial early.

UK surgical sealant film company Tissuemed Ltd. has announced the publication of a new clinical paper in World Neurosurgery relating to its self-adhesive dural sealant film products.

First and only 4-mm thrombectomy devices that can be deployed through catheters as small as 10/14 offer improved navigation and aspiration.

Peter Arduini becomes President and Chief Executive Officer at Integra as Stuart Essig is elevated to Executive Chairman of the Board.

Following FDA’s approval under Humanitarian Device Exemption rules of Synapse Biomedical’s NeurX Diaphragm Pacing System in September it has now released further information.

Stryker has announced its intention to implement focused workforce reductions of approximately 5% of its global workforce and other restructuring activities that are anticipated to reduce annual pre-tax operating costs by over $100 million beginning in 2013.

Brain stimulation has now been shown to offer significant relief to patients with intractable seizures for whom drugs and other treatments have not worked.

Millennium Research Group believes the market for neurosurgical and neurovascular devices will grow to $240 million by 2016

Pilot clinical trial indicates that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor